8-K: Evolus Reports Strong Q2 2026 Results, Raises Outlook

Evolus, Inc. announced robust second quarter 2026 financial results, including a 21% increase in net revenue and a third consecutive quarter of positive Adjusted EBITDA, leading to an improved full-year financial outlook.

Summary

• Evolus, Inc. reported second quarter 2026 net revenue of $84.1 million, a 21% increase year-over-year.
• The company achieved positive Adjusted EBITDA of $4.7 million, marking the third consecutive quarter of profitability on this metric, a significant improvement from a $7.9 million loss in the prior year's quarter.
• Full-year 2026 net revenue guidance has been raised to between $330 million and $337 million.
• Adjusted gross profit margin guidance for the full year was increased to 67.0%-67.5%.
• Non-GAAP operating expenses for the full year are now projected to be between $212 million and $216 million.
• The company expanded its global injectable portfolio with the addition of Profhilo for the U.S. market and the expansion of the Estyme franchise into Canada, Australia, and New Zealand.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive report, with strong revenue growth, a third consecutive quarter of positive Adjusted EBITDA, and an increased full-year financial outlook, alongside strategic product pipeline expansion.

Positives

• Total net revenue increased by 21% to $84.1 million in Q2 2026 compared to Q2 2025.
• Achieved positive Adjusted EBITDA of $4.7 million in Q2 2026, a $12.6 million year-over-year improvement.
• Raised full-year 2026 net revenue guidance to $330 million $337 million.
• Increased full-year 2026 adjusted gross profit margin guidance to 67.0% 67.5%.
• Expanded global injectable portfolio with Profhilo (U.S.) and Estyme (Canada, Australia, New Zealand).
• Customer reorder rates remain strong at over 70%.
• Evolus Rewards loyalty program members grew by 25% year-over-year to over 1.5 million.

Negatives

• Reported a GAAP operating loss of $4.5 million for Q2 2026.
• Total assets decreased from $225.9 million at the end of 2025 to $248.0 million at the end of Q2 2026, while total liabilities increased from $249.0 million to $278.9 million, resulting in a larger stockholders deficit of $(30.9) million.
• Cash and cash equivalents decreased from $53.8 million at the end of 2025 to $45.2 million at the end of Q2 2026.

Risks

• Reliance on consumer discretionary spending and unfavorable global economic conditions.
• Uncertainties related to customer and consumer adoption of Jeuveau and Evolysse.
• Competition and market dynamics in the aesthetics industry.
• Ability to successfully launch and commercialize products in new markets.
• Maintaining regulatory approvals for existing products and obtaining approvals for new candidates.
• Reliance on Symatese for regulatory approval of Evolysse HA gel products in the U.S.

Future Outlook

The company raised its full-year 2026 net revenue guidance to $330 million-$337 million and increased its adjusted gross profit margin guidance to 67.0%-67.5%. It also narrowed its non-GAAP operating expense guidance to $212 million-$216 million and reaffirmed a lowto mid-single digit Adjusted EBITDA margin outlook for 2026. The 2028 long-term outlook remains for total net revenue between $450 million and $500 million, with Adjusted EBITDA margins of 13% to 15%.

Management Comments

• "The increasing momentum of our portfolio focus has resulted in Evolus gaining significant share across injectable aesthetics during the second quarter, supported by double-digit growth for Jeuveau and accelerating adoption of Evolysse."
• "We delivered another quarter of consistent execution, highlighted by 21% revenue growth and a third consecutive quarter of positive Adjusted EBITDA, representing a $12.6 million improvement over the prior-year period."
• "Based on our first-half results, we are raising our full-year 2026 financial outlook while continuing to invest in strategic opportunities that strengthen our long-term growth profile."
• "Together, these milestones demonstrate the strength of our commercial platform and reinforce our ability to attract category leading partners across the global aesthetics market."

Industry Context

StockSavvy.ai notes that the injectable aesthetics market is showing signs of strengthening, with mid-single digit growth in the neurotoxin market and a return to positive growth in the hyaluronic acid category, which had experienced declines. Evolus's strategic expansion into new product categories like Profhilo and broader geographic reach for its HA gels align with industry trends towards diversified portfolios and global market penetration.

Stakeholder Impact

• Shareholders: Positive impact from raised financial outlook and improved profitability metrics, though GAAP losses and increasing liabilities are noted.
• Employees: Continued investment in strategic opportunities may support growth and job security.
• Customers/Practitioners: Expansion of product portfolio and loyalty programs like Evolus Rewards aim to enhance customer engagement and retention.
• Creditors: Increased liabilities and a growing stockholders deficit may be a concern, though cash position is noted.

Next Steps

• Continue advancing Evolysse Sculpt through the FDA review process with anticipated U.S. approval in Q4 2026.
• Commercialize Profhilo in the United States, with estimated peak annual revenue exceeding $100 million and anticipated commercialization in 2030.
• Commercialize the Estyme HA gel portfolio in Canada, Australia, and New Zealand, with expected commercialization in 2028.
• Continue to invest in strategic opportunities to strengthen long-term growth.

Key Dates

Recommendation

The company shows strong operational improvements with increased revenue and positive EBITDA, alongside a raised outlook. However, the continued GAAP operating losses, increasing liabilities, and shrinking cash reserves warrant a cautious 'hold' rating until sustained profitability and a stronger balance sheet are demonstrated.

Keywords

injectable aesthetics, neurotoxin, hyaluronic acid, Profhilo, Jeuveau, Evolysse, Estyme, financial results